Greencity Acquisition (GRCYF) 10-K/A 31 Mar 22 2020 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 28, 2022
Document and Entity Information [Abstract]
Document Type	10-K/A
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2020
Entity Registrant Name	Greencity Acquisition Corp
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Central Index Key	0001768910
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	true
Trading Symbol	GRCYU
Title of 12(b) Security	Units, each consisting of one Ordinary Share and one Warrant
Security Exchange Name.	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		5,260,000
Entity Voluntary Filers	No
Entity Public Float	$ 41,600,000
Amendment Description	Amendment No. 2

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash	$ 473,945	$ 526
Prepaid expenses and other current assets	125,420
Total Current Assets	599,365	526
Security deposit		4,663
Deferred offering costs		193,089
Marketable securities held in Trust Account	40,615,212
Total Assets	41,214,577	198,278
Current liabilities
Accrued expenses	76,649	289
Accrued offering costs	30,000	3,166
Promissory note - related party	394,590	196,495
Total Current Liabilities	501,239	199,950
Warrant Liabilities	2,930,000
Deferred underwriting fee payable	1,000,000
Total Liabilities	4,431,239	199,950
Commitments And Contingencies (note 7)
Ordinary shares subject to possible redemption, 4,000,000 shares at $10.15 per share	40,600,000
Shareholders' Deficit
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 1,260,000 and 1,150,000 shares issued and outstanding at December 31, 2020 and 2019, respectively	126	115
Additional paid in capital		24,885
Accumulated deficit	(3,816,788)	(26,672)
Total Shareholders' Deficit	(3,816,662)	(1,672)
Total Liabilities and Shareholders' Deficit	$ 41,214,577	$ 198,278

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Feb. 21, 2019
BALANCE SHEETS
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares, issued	1,260,000	1,150,000
Common stock, shares, outstanding	1,260,000	1,150,000
Ordinary shares subject to possible redemption, shares	4,000,000
Redemption price per share	$ 10.15

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating costs	$ (253,637)	$ (22,672)
Loss from operations	(253,637)	(22,672)
Other income (expense):
Interest earned on marketable securities held in Trust Account	14,324
Offering costs allocated to warrants	(55,162)
Change in fair value of warrant liabilities	(2,030,000)
Unrealized gain on marketable securities held in Trust Account	888
Other expense	(2,069,950)
Net loss	$ (2,323,587)	$ (22,672)
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,393,574	857,534
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,393,574	857,534
Basic net loss per ordinary shares subject to possible redemption	$ (1.68)	$ (0.03)
Diluted net loss per ordinary shares subject to possible redemption	$ (1.68)	$ (0.03)
Parent [Member]
Other income (expense):
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,214,918	857,534
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,214,918	857,534
Basic net loss per ordinary shares subject to possible redemption	$ (2.05)	$ (0.03)
Diluted net loss per ordinary shares subject to possible redemption	$ (2.05)	$ (0.03)
Shares Subject To Possible Redemption [Member]
Other income (expense):
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,704,918
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,704,918
Basic net loss per ordinary shares subject to possible redemption	$ 0.10
Diluted net loss per ordinary shares subject to possible redemption	$ 0.10

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)	Ordinary sharesIPO	Ordinary sharesPrivate placement	Ordinary shares	Additional paid-in capitalIPO	Additional paid-in capitalPrivate placement	Additional paid-in capitalUnit Purchase Option	Additional paid-in capital	Accumulated deficitIPO	Accumulated deficitPrivate placement	Accumulated deficitUnit Purchase Option	Accumulated deficit	IPO	Private placement	Unit Purchase Option	Total
Balance at Dec. 31, 2018							$ 25,000				$ (4,000)				$ 21,000
Balance (in shares) at Dec. 31, 2018			1
Issuance of ordinary shares to Sponsor			$ 115				(115)				0
Issuance of ordinary shares to Sponsor (in Shares)			1,149,999
Net Loss							0				(22,672)				(22,672)
Balance at Dec. 31, 2019			$ 115				24,885				(26,672)				(1,672)
Balance (in shares) at Dec. 31, 2019			1,150,000
Issuance of ordinary shares to Sponsor (in Shares)				4,000,000	260,000							4,000,000	260,000
Balance at Dec. 31, 2019			$ 115				24,885				(26,672)				(1,672)
Balance (in shares) at Dec. 31, 2019			1,150,000
Issuance of ordinary shares to Sponsor	$ 400	$ 26		$ 37,352,935	$ 2,599,974	$ 100		$ 0	$ 0	$ 0		$ 37,353,335	$ 2,600,000	$ 100
Issuance of ordinary shares to Sponsor (in Shares)	4,000,000	260,000		4,000,000	260,000							4,000,000	260,000
Forfeiture of Founder Shares (in value)			$ (15)				15				0				15
Forfeiture of Founder Shares (in shares)			(150,000)
Offering costs allocated to warrants							55,162				0				55,162
Private warrants - liabilities (As restated							(900,000)				0				(900,000)
Reclassification of ordinary shares subject to redemption (As restated)			$ (400)				(39,544,830)				0				(39,545,230)
Reclassification of ordinary shares subject to redemption (As restated) (in shares)			(4,000,000)
Allocation of offering costs to ordinary share subject to redemption							2,616,574				0				2,616,574
Accretion of carrying value to redemption value (As restated)							(2,204,815)				(1,466,529)				(3,671,344)
Net Loss							0				(2,323,587)				(2,323,587)
Balance at Dec. 31, 2020			$ 126				$ 0				$ (3,816,788)				$ (3,816,662)
Balance (in shares) at Dec. 31, 2020			1,260,000

STATEMENTS OF CHANGES IN SHAR_2

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) - shares	Apr. 12, 2021	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Issuance of ordinary shares to Sponsor (in Shares)	260,000
IPO
Issuance of ordinary shares to Sponsor (in Shares)		4,000,000	4,000,000	4,000,000	4,000,000
Private placement
Issuance of ordinary shares to Sponsor (in Shares)		260,000	260,000	260,000	260,000

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities:
Net Loss	$ (2,323,587)	$ (22,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account	(14,324)
Unrealized gain on marketable securities held in Trust Account	(888)
Change in fair value of warrant liabilities	2,030,000
Offering costs allocated to warrants	55,162
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(125,420)
Accrued expenses	76,360	(3,711)
Net cash used in operating activities	(302,697)	(26,383)
Cash Flows from Investing Activities:
Security deposit	4,663	(4,663)
Investment of cash into Trust Account	(40,600,000)
Net cash used in financing activities	(40,595,337)	(4,663)
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid	39,000,000
Proceeds from sale of Placement Units	2,600,000
Proceeds from sale of unit purchase option	100
Proceeds from promissory note - related party	198,095	365,500
Repayment of promissory note - related party		(194,000)
Payment of offering costs	(426,742)	(189,923)
Net cash provided by (used in) financing activities	41,371,453	(18,423)
Net Change in Cash	473,419	(49,469)
Cash - Beginning	526	49,995
Cash - Ending	473,945	526
Non-Cash Investing and Financing Activities:
Change in value of ordinary shares subject to possible redemption	39,545,230
Allocation of offering costs to ordinary share subject to redemption	2,616,574
Accretion of carrying value to redemption value	3,671,344
Deferred underwriting fee payable	1,000,000
Offering costs included in accrued offering costs	30,000	3,166
Conversion of advance from related party to promissory note - related party		$ 24,995
Forfeiture of Founder Shares	$ (15)

DESCRIPTION OF ORGANIZATION AND

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	12 Months Ended
	Dec. 31, 2020
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Greencity Acquisition Corporation (the “Company”) is a blank check company incorporated in the Cayman Islands on May 14, 2018. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses that have a connection to the Asia market. At December 31, 2020, the Company had not commenced any operations. All activity through December 31, 2020 relates to the Company’s formation and the Initial Public Offering (as defined below). The registration statement for the Company’s Initial Public Offering was declared effective on July 23, 2020. On July 28, 2020, the Company consummated the Initial Public Offering of 4,000,000 units (the “Units” and, with respect to the ordinary shares included in the Units sold, the “Public Shares”), generating gross proceeds of $40,000,000, which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 260,000 units (the “Private Units”) at a price of $10.00 per Private Unit in a private placement to Cynthia Management Corporation (the “Sponsor”), generating gross proceeds of $2,600,000, which is described in Note 5. Transaction costs amounted to $2,646,665, consisting of $1,000,000 of underwriting fees, $1,000,000 of deferred underwriting fees and $646,665 of other offering costs. Following the closing of the Initial Public Offering on July 28, 2020, an amount of $40,600,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Units was placed in a trust account (the “Trust Account”) invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (less any deferred underwriting commissions and taxes payable on interest earned) at the time of the signing of an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, if the Company is no longer a foreign private issuer, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent. If the Company continues to be a foreign private issuer or if a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.15 per Public Share, subject to increase of up to an additional $0.30 per Public Share in the event that the Sponsor elects to extend the period of time to consummate a Business Combination (see below), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. The Sponsor and any of the Company’s officers or directors that may hold founder shares (the “initial shareholders”) will agree (a) to vote their founder shares, the ordinary shares included in the Private Units (the “Private Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the founder shares) and Private Shares into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the Amended and Restated Memorandum and Articles of Association relating to shareholders’ rights of pre-Business Combination activity and (d) that the founder shares and Private Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the initial shareholders will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination. The Company will have until July 28, 2021 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by July 28, 2021, the Company may extend the period of time to consummate a Business Combination up to nine times, each by an additional month (for a total of 21 months to complete a Business Combination (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $133,334, up to an aggregate of $1,200,000, or $0.30 per Public Share, on or prior to the date of the applicable deadline, for each monthly extension. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below (i) $10.15 per share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Liquidity and Going Concern As of December 31, 2020, the Company had $473,945 in its operating bank accounts and working capital of $98,126. Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. To complete a Business Combination, the Company will need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through one year from the date of these financial statements if a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	12 Months Ended
	Dec. 31, 2020
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). Specifically, the SEC Statement focused on certain provisions that provided for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant, which terms are similar to those contained in the warrant agreement governing the Company’s warrants. As a result of the SEC Statement, the Company reevaluated the accounting treatment of the 260,000 warrants that were issued to the Company’s sponsor in a private placement that closed concurrently with the closing of the Initial Public Offering (the “Private Warrants”). The Company previously accounted for the Private Warrants as components of equity. In further consideration of the guidance in Accounting Standards Codification (“ASC”) 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity (“ASC 815”), the Company concluded that a provision in the warrant agreement related to certain transfer provisions precludes the Private Warrants from being accounted for as components of equity. As the Private Warrants meet the definition of a derivative as contemplated in ASC 815, the Private Warrants should be recorded as derivative liabilities on the balance sheet and measured at fair value at inception (on the date of the Initial Public Offering) and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the Statements of Operations in the period of change. In addition, in preparation of the Company’s financial statements as of and for the year ended December 31, 2021, the Company concluded it should restate its financial statements to classify all ordinary shares subject to possible redemption in temporary equity. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, ASC Topic 480, Distinguishing Liabilities from Equity (ASC 480), paragraph 10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company had previously classified a portion of its ordinary shares in permanent equity. Although the Company did not specify a maximum redemption threshold, its charter provides that currently, the Company will not redeem its public shares in an amount that would cause its net tangible assets to be less than $5,000,001. The Company considered that the threshold would not change the nature of the underlying shares as redeemable and thus would be required to be disclosed outside equity. As a result, the Company restated its previously filed financial statements to classify all ordinary shares as temporary equity and to recognize accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. The change in the carrying value of redeemable shares of ordinary shares resulted in charges against accumulated deficit. The following tables summarize the effect of the restatement on each financial statement line item as of the dates, and for the period, indicated: Adjustment #1 refer to reclassification of public warrants from warrant liabilities to equity component. Adjustment #2 refer to reclassification of all public shares to temporary equity. As Previously Balance Sheet as of July 28, 2020 (Audited) Reported Adjustments #1 Adjustments #2 As Restated Warrant Liabilities — 900,000 — 900,000 Ordinary shares subject to possible redemption 34,944,653 (900,000) 6,555,347 40,600,000 Ordinary shares 197 9 (80) 126 Additional paid-in capital 5,033,585 55,153 (5,088,738) — Accumulated deficit (33,779) (55,162) (1,466,529) (1,555,470) Total Shareholders’ Equity (Deficit) — (6,555,347) (1,555,344) Number of shares subject to possible redemption 3,442,823 (88,670) 645,847 4,000,000 Balance Sheet as of September 30, 2020 (Unaudited) Warrant Liabilities — 990,000 — 990,000 Ordinary shares subject to possible redemption 34,835,933 (990,006) 6,754,073 40,600,000 Ordinary shares 183 10 (67) 126 Additional paid-in capital 5,142,319 145,158 (5,287,477) — Accumulated deficit (142,500) (145,162) (1,466,529) (1,754,191) Total Shareholders’ Equity (Deficit) 5,000,002 6 (6,754,073) (1,754,065) Number of shares subject to possible redemption 3,431,787 (97,528) 665,741 4,000,000 Balance Sheet as of December 31, 2020 (Audited) Warrant Liabilities — 2,930,000 — 2,930,000 Ordinary shares subject to possible redemption 34,713,334 (2,929,997) 8,816,663 40,600,000 Ordinary shares 184 29 (87) 126 Additional paid-in capital 5,264,917 2,085,130 (7,350,047) — Accumulated deficit (265,097) (2,085,162) (1,466,529) (3,816,788) Total Shareholders’ Equity (Deficit) 5,000,004 (3) (8,816,663) (3,816,662) Number of shares subject to possible redemption 3,418,752 (288,562) 869,810 4,000,000 Statement of Operations for the three months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (90,000) — (90,000) Net loss (109,200) (145,162) — (254,362) Weighted average shares outstanding, basic and diluted 1,577,353 62,648 (341,740) 1,298,261 Basic and diluted net loss per share, ordinary shares (0.07) (0.09) (0.80) (0.96) Statement of Operations for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (90,000) — (90,000) Net loss (115,828) (145,162) — (260,990) Weighted average shares outstanding, basic and diluted 1,193,856 21,035 (15,110) 1,199,781 Basic and diluted net loss per share, ordinary shares (0.10) (0.12) (1.62) (1.84) Statement of Operations for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (2,030,000) — (2,030,000) Net loss (238,425) (2,085,162) — (2,323,587) Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption 3,436,356 (93,861) (1,637,577) 1,704,918 Basic and diluted weighted average ordinary shares outstanding 1,353,312 40,262 (178,656) 1,214,918 Basic and diluted net loss per share, ordinary shares (0.19) (1.49) (0.37) (2.05) Statement of Cash Flows for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — 55,162 — 55,162 Change in fair value of warrant liabilities — 90,000 — 90,000 Net loss (115,828) (145,162) — (260,990) Initial classification of ordinary shares subject to possible redemption 34,944,655 — (34,944,655) — Change in value of ordinary shares subject to possible redemption (108,722) (90,006) 39,545,230 Allocation of offering costs to ordinary shares subject to possible redemption — — Accretion of carrying value to redemption value — — Statement of Cash Flows for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance — 55,162 — 55,162 Change in fair value of warrant liabilities — 2,030,000 — 2,030,000 Net loss (238,425) (2,085,162) — (2,323,587) Initial classification of ordinary shares subject to possible redemption 34,944,655 — (34,944,655) — Change in value of ordinary shares subject to possible redemption (231,319) (2,029,999) 41,806,548 39,545,230 Allocation of offering costs to ordinary shares subject to possible redemption — — 2,616,574 2,616,574 Accretion of carrying value to redemption value — — 3,671,344 3,671,344 Statement of Changes in Shareholder’s Equity for the three and nine months ended September 30, 2020 (Unaudited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital 37,352,935 70,000 (70,000) 37,352,935 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 70,000 (70,000) 37,353,335 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 70,000 2,599,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 70,000 2,600,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,835,590) 989,996 (5,699,236) (39,544,830) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,835,933) 990,006 (5,699,303) (39,545,230) Allocation of offering costs to ordinary shares subject to possible redemption – Additional Paid-in Capital — — 2,616,574 2,616,574 Allocation of offering costs to ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity — — 2,616,574 2,616,574 Accretion of carrying value to redemption value – Additional Paid-in Capital — — (2,204,815) (2,204,815) Accretion of carrying value to redemption value – Accumulated deficit — — (1,466,529) (1,466,529) Accretion of carrying value to redemption value – Total Shareholder’s (Deficit) Equity — — (3,671,344) (3,671,344) Statement of Changes in Shareholder’s Equity for the year ended December 31, 2020 (Audited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital 37,352,935 (774,838) 774,838 37,352,935 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 774,838 37,353,335 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 70,000 2,599,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 70,000 2,600,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,712,992) 2,929,968 (7,761,806) (39,544,830) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,713,334) 2,929,997 (7,761,893) (39,545,230) Allocation of offering costs to ordinary shares subject to possible redemption – Additional Paid-in Capital — — 2,616,574 2,616,574 Allocation of offering costs to ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity — — 2,616,574 2,616,574 Accretion of carrying value to redemption value – Additional Paid-in Capital — — (2,204,815) (2,204,815) Accretion of carrying value to redemption value – Accumulated deficit — — (1,466,529) (1,466,529) Accretion of carrying value to redemption value – Total Shareholder’s (Deficit) Equity — — (3,671,344) (3,671,344)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“USGAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020 and 2019. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. Marketable Securities Held in Trust Account At December 31, 2020, substantially all of the assets held in the Trust Account were held in money market funds, which are invested in U.S. Treasury Securities. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering” . Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Accordingly, on December 31, 2020, offering costs totaling $2,646,665 consist of $1,000,000 of underwriting fee, $1,000,000 of deferred underwriting fee and $646,665 of other offering costs. The transaction costs were allocated based on the relative fair value basis, compared to the total offering proceeds, between the fair value of the public warrant liabilities and the ordinary shares. Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of December 31, 2020 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented. Net Loss Per Ordinary Share (Restated) The Company complies with accounting and disclosure requirements of ASC 260, Earnings Per Share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable common stock and non-redeemable common stock and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable common stock. Any remeasurement of the accretion to redemption value of the common stock subject to possible redemption was considered to be dividends paid to the public stockholders. As of December 31, 2020, the Company has not considered the effect of the warrants sold in the Initial Public Offering to purchase an aggregate of 1,300,000 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants is contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive and the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic (income) loss per share for the period presented. The net loss per share presented in the statement of operations is based on the following: Year Ended Year Ended December 31, 2020 December 31, 2019 Net loss $ (2,323,587) $ (22,672) Accretion of carrying value to redemption value (3,671,344) — Net loss including accretion of carrying value to redemption value $ (5,994,931) $ (22,672) For the For the Year Ended Year Ended December 31, 2020 December 31, 2019 Redeemable Non-Redeemable Redeemable Non-Redeemable Common Stock Common Stock Common Stock Common Stock Basic and diluted net loss per share: Numerators: Allocation of net loss including carrying value to redemption value $ (3,500,495) $ (2,494,438) $ — $ — Accretion of carrying value to redemption value 3,671,344 — — — Allocation of net income (loss) $ 170,851 $ (2,494,438) $ — $ — Denominators: Weighted-average shares outstanding 1,704,918 1,214,918 — 857,534 Basic and diluted net income (loss) per share $ 0.10 $ (2.05) $ — $ (0.03) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying financial statements, primarily due to their short-term nature, not including the warrants. Derivative Financial Instruments We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument is required within 12 months of the balance sheet date. Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

INITIAL PUBLIC OFFERING

INITIAL PUBLIC OFFERING	12 Months Ended
	Dec. 31, 2020
INITIAL PUBLIC OFFERING
INITIAL PUBLIC OFFERING	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 4,000,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and one redeemable warrant (“Public Warrant”). Each Public Warrant will entitle the holder to purchase one-half of one ordinary share at an exercise price of $11.50 per whole share (see Note 9).

PRIVATE PLACEMENT

PRIVATE PLACEMENT	12 Months Ended
	Dec. 31, 2020
PRIVATE PLACEMENT.
PRIVATE PLACEMENT	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 260,000 Private Units at a price of $10.00 per Private Unit, for an aggregate purchase price of $2,600,000. The proceeds from the Private Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. The Private Units are identical to the Units sold in the Initial Public Offering, except for the private warrants (“Private Warrants”), as described in Note 9. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Units and underlying securities will be worthless.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares In December 2018, the Company received $25,000 for the anticipated issuance of 1,150,000 founder shares to the Sponsor. As of December 31, 2018, one founder share was issued to the Sponsor. The remaining 1,149,999 founder shares were issued to the Sponsor on February 21, 2019. The 1,150,000 founder shares included an aggregate of up to 150,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the Sponsor will collectively own 20% of the Company’s issued and outstanding shares after the Initial Public Offering. On September 10, 2020, the underwriters’ election to exercise their over-allotment option expired unexercised, resulting in the forfeiture of 150,000 founder shares. Accordingly, there were 1,000,000 Founder Shares issued and outstanding. The initial shareholders have agreed not to transfer, assign or sell any of the founder shares (except to certain permitted transferees) until, with respect to 50% of the founder shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination, with respect to the remaining 50% of the founder shares, upon six months after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. Administrative Services Arrangement The Company entered into an agreement whereby, commencing on July 24, 2020, through the earlier of the Company’s consummation of a Business Combination and its liquidation, the Company will pay the Sponsor a total of $10,000 per month for certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. For the year ended December 31, 2020, the Company incurred $50,000 in fees for these services, of which such amount is included within accrued expenses in the accompanying balance sheets. Advance from Related Party As of December 31, 2018, the Sponsor advanced the Company an aggregate of $24,995. The advance was non-interest bearing and due on demand. In February 2019, the advance was converted into a promissory note. As of December 31, 2020 and 2019, there were no advances outstanding. Promissory Note — Related Party On February 21, 2019, the Company issued a non-interest bearing, unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. On June 30, 2019, the Company amended the promissory note such that the Company may borrow up to an aggregate total principal amount of $500,000 (the “Promissory Note”) and on June 20, 2020, the Company further amended the Promissory Note such that the Promissory Note is payable on the earlier of (i) December 31, 2020 or (ii) the consummation of the Initial Public Offering. In connection with the Promissory Note, the Company converted $24,995 in advances as of December 31, 2018 into amounts outstanding under the Promissory Note. On July 28, 2020, the Company amended the Promissory Note such that it is payable upon the consummation of a Business Combination. At December 31, 2020 and 2019, there was $394,590 and $196,495, respectively, outstanding under the Promissory Note. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Promissory Note but no proceeds held in the Trust Account would be used to repay the Promissory Note. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Related Party Extension Loans As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to nine times, each by an additional month (for a total of 21 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $133,334 ($0.033 per Public Share), up to an aggregate of $1,200,000, or $0.30 per Public Share, on or prior to the date of the applicable deadline, for each monthly extension. Any such payments would be made in the form of a loan. The terms of the promissory note to be issued in connection with any such loans have not yet been negotiated. If the Company completes a Business Combination, the Company would repay such loaned amounts out of the proceeds of the Trust Account released to the Company. If the Company does not complete a Business Combination, the Company will not repay such loans. Furthermore, the letter agreement with the initial shareholders contains a provision pursuant to which the Sponsor has agreed to waive its right to be repaid for such loans in the event that the Company does not complete a Business Combination. The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for the Company to complete a Business Combination.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Registration Rights Pursuant to a registration rights agreement entered into on July 23, 2020, the holders of the founder shares, Private Units (and their underlying securities), the shares underlying the warrants underlying the unit purchase option issued to the underwriters and any Units that may be issued upon conversion of the Working Capital Loans (and underlying securities) are entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. Notwithstanding the foregoing, the underwriters may not exercise their demand and “piggyback” registration rights after five (5) and seven (7) years after the effective date of the registration statement and may not exercise their demand rights on more than one occasion. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option to purchase up to 600,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. On September 10, 2020, the underwriters’ election to exercise their over-allotment option expired unexercised. The underwriters were paid a cash underwriting discount of two and one-half percent (2.5%) of the gross proceeds of the Initial Public Offering, or $1,000,000. The underwriters are entitled to a deferred fee of two and one-half percent (2.5%) of the gross proceeds of the Initial Public Offering, or $1,000,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement.

SHAREHOLDERS' DEFICIT

SHAREHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2020
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY	NOTE 8. SHAREHOLDERS’ DEFICIT Preference Shares — On February 21, 2019, the Company filed an Amended and Restated Memorandum and Articles of Incorporation, pursuant to which the Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. At December 31, 2020 and 2019, there were no preference shares designated, issued or outstanding. Ordinary Shares — On February 21, 2019, the Company filed an Amended and Restated Memorandum and Articles of Incorporation, pursuant to which the Company is authorized to issue 100,000,000 ordinary shares, with a par value of $0.0001 per share. Holders of the ordinary shares are entitled to one vote for each ordinary share. As of December 31, 2020 and 2019, there were 1,260,000 and 1,150,000 ordinary shares issued and outstanding, excluding 4,000,000 and 0 ordinary shares subject to possible redemption, respectively. Unit Purchase Option On July 28, 2020, the Company sold the underwriter (and/or its designees), for $100, an option to purchase up to 240,000 Units exercisable at $11.00 per Unit (or an aggregate exercise price of $2,640,000) commencing on the later of the consummation of a Business Combination and January 28, 2021. The unit purchase option may be exercised for cash or on a cashless basis, at the holder’s option, and expires five years from the effective date of the registration statement related to the Initial Public Offering. The Units issuable upon exercise of the option are identical to those offered in the Initial Public Offering. The Company accounted for the unit purchase option as liability classification. The unit purchase option is valued based on the fair value of the public share estimated at the redemption value plus the fair value of the warrants. These amounts are below the exercise price of the unit purchase option therefore the probability of exercise is low resulting in a de minimus value for the unit purchase option. The option and such units purchased pursuant to the option, as well as the ordinary shares underlying such units, the warrants included in such units, and the shares underlying such warrants, have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA’s NASDAQ Conduct Rules. Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated for a one-year period (including the foregoing 180-day period) following July 28, 2020 except to any underwriter and selected dealer participating in the Initial Public Offering and their bona fide officers or partners. The option grants to holders demand and “piggy-back” rights for periods of five and seven years, respectively, from July 28, 2020 with respect to the registration under the Securities Act of the securities directly and indirectly issuable upon exercise of the option. The Company will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of units issuable upon exercise of the option may be adjusted in certain circumstances including in the event of a stock dividend, or the Company’s recapitalization, reorganization, merger or consolidation. However, the option will not be adjusted for issuances of ordinary shares at a price below its exercise price.

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2020
WARRANTS.
WARRANTS	NOTE 9. WARRANTS Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) the consummation of a Business Combination or (b) 12 months from the effective date of the registration statement relating to the Initial Public Offering. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon the exercise of the Public Warrants is not effective within 60 days, the holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. Redemption of warrants when the price per share of ordinary shares equals or exceeds $16.50. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants (except with respect to the Private Placement Warrants): · in whole and not in part, · at a price of $0.01 per warrant, · upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder, · if, and only if, the reported last sale price of the ordinary shares equal or exceed $16.50 per share, (as adjusted for share splits, share capitalizations, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders, and · if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $16.50 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 165% of the higher of the Market Value and the Newly Issued Price. The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the ordinary shares issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions and the Private Warrants underlying the Private Units issued to the underwriter may not be exercised after five years from the effective date of the Initial Public Offering. Additionally, the Private Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2020
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 10. FAIR VALUE MEASUREMENTS (RESTATED) The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other December 31, 2020 Active Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: U.S. Treasury Securities held in Trust Account* $ 40,615,212 $ 40,615,212 $ — $ — Liabilities: Derivative warrant liabilities – Public warrants $ 2,740,000 $ 2,740,000 $ — $ — Derivative warrant liabilities – Private warrants 190,000 — — 190,000 Total fair value (As restated) $ 2,930,000 $ 2,740,000 $ — $ 190,000 *included in cash and investments held in trust account on the Company’s balance sheet. The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Balance Sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Statement of Operations. The Company established the initial fair value of the Public Warrants and Private Warrants on July 28, 2020, the date of the Company’s IPO, using a binomial model for Public Warrants and Black-Scholes model for Private Warrants. Due to the use of quoted prices in an active market (Level 1) to measure the fair value of the Public Warrants, subsequent to initial measurement, the Company had transfer out of Level 3 of $190,000 at December 31, 2020. The key inputs into the binomial model and modified Black-Scholes model were as follows at their measurement dates: July 28, 2020 September 30, 2020 December 31, 2020 (Initial (Subsequent (Subsequent measurement) measurement) measurement) Input Share price $ 9.99 $ 9.91 $ 10.08 Risk-free interest rate 0.26 % 0.28 % 0.36 % Volatility 10 % 10 % 20 % Exercise price $ 11.50 $ 11.50 $ 11.50 Warrant life 5 years 5 years 5 years The following table presents the changes in fair value of warrant liabilities: Public Private Total Warrants Warrants Warrants Fair Value at July 28, 2020 $ 830,000 $ 70,000 $ 900,000 Change in fair value of public and private warrants 1,910,000 120,000 2,030,000 Fair Value at December 31, 2020 $ 2,740,000 $ 190,000 $ 2,930,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 11. SUBSEQUENT EVENTS On February 2, 2022 and March 24, 2022, the Company’s Sponsor deposited into the Company’s trust account an aggregate of $400,002, representing $0.033 per public share of the Company, in order to extend the period of time the Company has to consummate a business combination by one month to April 28, 2022. On July 21,2021, August 31,2021, September 24,2021, October 27, 2021 and December 31,2021, the Company issued unsecured promissory note, in an amount of $800,004, to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business combination.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation	Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“USGAAP”) and pursuant to the rules and regulations of the SEC.
Emerging growth company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020 and 2019.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At December 31, 2020, substantially all of the assets held in the Trust Account were held in money market funds, which are invested in U.S. Treasury Securities.
Offering Costs	Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering” . Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Accordingly, on December 31, 2020, offering costs totaling $2,646,665 consist of $1,000,000 of underwriting fee, $1,000,000 of deferred underwriting fee and $646,665 of other offering costs. The transaction costs were allocated based on the relative fair value basis, compared to the total offering proceeds, between the fair value of the public warrant liabilities and the ordinary shares.
Ordinary Shares Subject to Possible Redemption	Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets.
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of December 31, 2020 and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented.
Net Loss Per Ordinary Share (Restated)	Net Loss Per Ordinary Share (Restated) The Company complies with accounting and disclosure requirements of ASC 260, Earnings Per Share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable common stock and non-redeemable common stock and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable common stock. Any remeasurement of the accretion to redemption value of the common stock subject to possible redemption was considered to be dividends paid to the public stockholders. As of December 31, 2020, the Company has not considered the effect of the warrants sold in the Initial Public Offering to purchase an aggregate of 1,300,000 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants is contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive and the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic (income) loss per share for the period presented. The net loss per share presented in the statement of operations is based on the following: Year Ended Year Ended December 31, 2020 December 31, 2019 Net loss $ (2,323,587) $ (22,672) Accretion of carrying value to redemption value (3,671,344) — Net loss including accretion of carrying value to redemption value $ (5,994,931) $ (22,672) For the For the Year Ended Year Ended December 31, 2020 December 31, 2019 Redeemable Non-Redeemable Redeemable Non-Redeemable Common Stock Common Stock Common Stock Common Stock Basic and diluted net loss per share: Numerators: Allocation of net loss including carrying value to redemption value $ (3,500,495) $ (2,494,438) $ — $ — Accretion of carrying value to redemption value 3,671,344 — — — Allocation of net income (loss) $ 170,851 $ (2,494,438) $ — $ — Denominators: Weighted-average shares outstanding 1,704,918 1,214,918 — 857,534 Basic and diluted net income (loss) per share $ 0.10 $ (2.05) $ — $ (0.03)
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying financial statements, primarily due to their short-term nature, not including the warrants.
Derivative Financial Instruments	Derivative Financial Instruments We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument is required within 12 months of the balance sheet date.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
Schedule of restatement on the balance sheet	As Previously Balance Sheet as of July 28, 2020 (Audited) Reported Adjustments #1 Adjustments #2 As Restated Warrant Liabilities — 900,000 — 900,000 Ordinary shares subject to possible redemption 34,944,653 (900,000) 6,555,347 40,600,000 Ordinary shares 197 9 (80) 126 Additional paid-in capital 5,033,585 55,153 (5,088,738) — Accumulated deficit (33,779) (55,162) (1,466,529) (1,555,470) Total Shareholders’ Equity (Deficit) — (6,555,347) (1,555,344) Number of shares subject to possible redemption 3,442,823 (88,670) 645,847 4,000,000 Balance Sheet as of September 30, 2020 (Unaudited) Warrant Liabilities — 990,000 — 990,000 Ordinary shares subject to possible redemption 34,835,933 (990,006) 6,754,073 40,600,000 Ordinary shares 183 10 (67) 126 Additional paid-in capital 5,142,319 145,158 (5,287,477) — Accumulated deficit (142,500) (145,162) (1,466,529) (1,754,191) Total Shareholders’ Equity (Deficit) 5,000,002 6 (6,754,073) (1,754,065) Number of shares subject to possible redemption 3,431,787 (97,528) 665,741 4,000,000 Balance Sheet as of December 31, 2020 (Audited) Warrant Liabilities — 2,930,000 — 2,930,000 Ordinary shares subject to possible redemption 34,713,334 (2,929,997) 8,816,663 40,600,000 Ordinary shares 184 29 (87) 126 Additional paid-in capital 5,264,917 2,085,130 (7,350,047) — Accumulated deficit (265,097) (2,085,162) (1,466,529) (3,816,788) Total Shareholders’ Equity (Deficit) 5,000,004 (3) (8,816,663) (3,816,662) Number of shares subject to possible redemption 3,418,752 (288,562) 869,810 4,000,000 Statement of Operations for the three months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (90,000) — (90,000) Net loss (109,200) (145,162) — (254,362) Weighted average shares outstanding, basic and diluted 1,577,353 62,648 (341,740) 1,298,261 Basic and diluted net loss per share, ordinary shares (0.07) (0.09) (0.80) (0.96) Statement of Operations for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (90,000) — (90,000) Net loss (115,828) (145,162) — (260,990) Weighted average shares outstanding, basic and diluted 1,193,856 21,035 (15,110) 1,199,781 Basic and diluted net loss per share, ordinary shares (0.10) (0.12) (1.62) (1.84) Statement of Operations for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance — (55,162) — (55,162) Change in fair value of warrant liabilities — (2,030,000) — (2,030,000) Net loss (238,425) (2,085,162) — (2,323,587) Basic and diluted weighted average shares outstanding, Ordinary shares subject to possible redemption 3,436,356 (93,861) (1,637,577) 1,704,918 Basic and diluted weighted average ordinary shares outstanding 1,353,312 40,262 (178,656) 1,214,918 Basic and diluted net loss per share, ordinary shares (0.19) (1.49) (0.37) (2.05) Statement of Cash Flows for the nine months ended September 30, 2020 (Unaudited) Offering expenses related to warrant issuance — 55,162 — 55,162 Change in fair value of warrant liabilities — 90,000 — 90,000 Net loss (115,828) (145,162) — (260,990) Initial classification of ordinary shares subject to possible redemption 34,944,655 — (34,944,655) — Change in value of ordinary shares subject to possible redemption (108,722) (90,006) 39,545,230 Allocation of offering costs to ordinary shares subject to possible redemption — — Accretion of carrying value to redemption value — — Statement of Cash Flows for the year ended December 31, 2020 (Audited) Offering expenses related to warrant issuance — 55,162 — 55,162 Change in fair value of warrant liabilities — 2,030,000 — 2,030,000 Net loss (238,425) (2,085,162) — (2,323,587) Initial classification of ordinary shares subject to possible redemption 34,944,655 — (34,944,655) — Change in value of ordinary shares subject to possible redemption (231,319) (2,029,999) 41,806,548 39,545,230 Allocation of offering costs to ordinary shares subject to possible redemption — — 2,616,574 2,616,574 Accretion of carrying value to redemption value — — 3,671,344 3,671,344 Statement of Changes in Shareholder’s Equity for the three and nine months ended September 30, 2020 (Unaudited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital 37,352,935 70,000 (70,000) 37,352,935 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 70,000 (70,000) 37,353,335 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 70,000 2,599,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 70,000 2,600,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,835,590) 989,996 (5,699,236) (39,544,830) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,835,933) 990,006 (5,699,303) (39,545,230) Allocation of offering costs to ordinary shares subject to possible redemption – Additional Paid-in Capital — — 2,616,574 2,616,574 Allocation of offering costs to ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity — — 2,616,574 2,616,574 Accretion of carrying value to redemption value – Additional Paid-in Capital — — (2,204,815) (2,204,815) Accretion of carrying value to redemption value – Accumulated deficit — — (1,466,529) (1,466,529) Accretion of carrying value to redemption value – Total Shareholder’s (Deficit) Equity — — (3,671,344) (3,671,344) Statement of Changes in Shareholder’s Equity for the year ended December 31, 2020 (Audited) Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Additional Paid-in Capital 37,352,935 (774,838) 774,838 37,352,935 Sales of 4,000,000 Units, net of underwriting discounts and offering costs – Total Shareholder’s (Deficit) Equity 37,353,335 (774,838) 774,838 37,353,335 Sale of 260,000 Private Units – Additional Paid-in Capital 2,599,974 (70,000) 70,000 2,599,974 Sale of 260,000 Private Units – Total Shareholder’s (Deficit) Equity 2,600,000 (70,000) 70,000 2,600,000 Ordinary shares subject to possible redemption – Additional Paid-in Capital (34,712,992) 2,929,968 (7,761,806) (39,544,830) Ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity (34,713,334) 2,929,997 (7,761,893) (39,545,230) Allocation of offering costs to ordinary shares subject to possible redemption – Additional Paid-in Capital — — 2,616,574 2,616,574 Allocation of offering costs to ordinary shares subject to possible redemption – Total Shareholder’s (Deficit) Equity — — 2,616,574 2,616,574 Accretion of carrying value to redemption value – Additional Paid-in Capital — — (2,204,815) (2,204,815) Accretion of carrying value to redemption value – Accumulated deficit — — (1,466,529) (1,466,529) Accretion of carrying value to redemption value – Total Shareholder’s (Deficit) Equity — — (3,671,344) (3,671,344)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of reconciliation of net loss per ordinary share	Year Ended Year Ended December 31, 2020 December 31, 2019 Net loss $ (2,323,587) $ (22,672) Accretion of carrying value to redemption value (3,671,344) — Net loss including accretion of carrying value to redemption value $ (5,994,931) $ (22,672) For the For the Year Ended Year Ended December 31, 2020 December 31, 2019 Redeemable Non-Redeemable Redeemable Non-Redeemable Common Stock Common Stock Common Stock Common Stock Basic and diluted net loss per share: Numerators: Allocation of net loss including carrying value to redemption value $ (3,500,495) $ (2,494,438) $ — $ — Accretion of carrying value to redemption value 3,671,344 — — — Allocation of net income (loss) $ 170,851 $ (2,494,438) $ — $ — Denominators: Weighted-average shares outstanding 1,704,918 1,214,918 — 857,534 Basic and diluted net income (loss) per share $ 0.10 $ (2.05) $ — $ (0.03)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
FAIR VALUE MEASUREMENTS
Schedule of Company's asset measured at fair value on a recurring basis	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other December 31, 2020 Active Markets Observable Inputs Unobservable Inputs Description (Level 1) (Level 2) (Level 3) Assets: U.S. Treasury Securities held in Trust Account* $ 40,615,212 $ 40,615,212 $ — $ — Liabilities: Derivative warrant liabilities – Public warrants $ 2,740,000 $ 2,740,000 $ — $ — Derivative warrant liabilities – Private warrants 190,000 — — 190,000 Total fair value (As restated) $ 2,930,000 $ 2,740,000 $ — $ 190,000 *included in cash and investments held in trust account on the Company’s balance sheet.
Schedule of initial measurement of key inputs	July 28, 2020 September 30, 2020 December 31, 2020 (Initial (Subsequent (Subsequent measurement) measurement) measurement) Input Share price $ 9.99 $ 9.91 $ 10.08 Risk-free interest rate 0.26 % 0.28 % 0.36 % Volatility 10 % 10 % 20 % Exercise price $ 11.50 $ 11.50 $ 11.50 Warrant life 5 years 5 years 5 years
Schedule of changes Level 3 liabilities	Public Private Total Warrants Warrants Warrants Fair Value at July 28, 2020 $ 830,000 $ 70,000 $ 900,000 Change in fair value of public and private warrants 1,910,000 120,000 2,030,000 Fair Value at December 31, 2020 $ 2,740,000 $ 190,000 $ 2,930,000

DESCRIPTION OF ORGANIZATION A_2

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details) - USD ($)	Mar. 24, 2022	Feb. 02, 2022	Apr. 12, 2021	Jul. 28, 2020	Feb. 21, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)			260,000
Gross proceeds from issuance of warrants								$ 2,600,000
Deferred underwriting fee								1,000,000
Cash								473,945		$ 526
Working capital deficit								$ 98,126
Share redemption (as a percent)								15.00%
Redemption Price Per Share								$ 10.15
Redemption price per share								$ 10.15
Extension period of time to consummate a Business Combination								21 months
Related party transaction proceeds from exercise of shares								$ 1,200,000
Percentage of shares of stock the Company is obligated to redeem without consummating a business combination								100.00%
Operating bank accounts								$ 473,945
Dissolution expenses								$ 50,000
Common stock, par or stated value per share					$ 0.0001			$ 0.0001		$ 0.0001
Related party transaction, Amount deposited into trust account by sponsor								$ 133,334
Related Party Loans
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Related party transaction, Amount deposited into trust account by sponsor								$ 133,334
Subsequent event
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Related party transaction, Amount deposited into trust account by sponsor	$ 400,002	$ 400,002
Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Redemption price per share								$ 0.30
Sponsor
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)					1,149,999				1
Proceeds from issuance IPO				$ 40,600,000
Ownership interest to be acquired on post-transaction company								50.00%
Shares issued price per share				$ 10.15
Fair value on assets held In trust (as a percent)								80.00%
Business combination limit on net tangible assets								$ 5,000,001
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)				4,000,000		4,000,000	4,000,000	4,000,000
Proceeds from issuance IPO				$ 40,000,000
Exercise price of warrants or rights								$ 11.50
Transaction cost				2,646,665
Underwriting fees				1,000,000
Deferred underwriting fee				1,000,000
Other offering costs				$ 646,665
Shares issued price per share								$ 10
Number of ordinary shares per unit								1
Warrants exercise ratio								0.5
Private placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock issued (in shares)				260,000		260,000	260,000	260,000
Gross proceeds from issuance of warrants				$ 2,600,000
Shares issued price per share				$ 10				$ 10

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Balance Sheet (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Jul. 28, 2020	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant Liabilities	$ 2,930,000
Ordinary shares subject to possible redemption	40,600,000
Ordinary shares	126			$ 115
Additional paid in capital				24,885
Accumulated deficit	(3,816,788)			(26,672)
Total Shareholders' Equity (Deficit)	$ (3,816,662)			$ (1,672)	$ 21,000
Ordinary shares subject to possible redemption, shares	4,000,000
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant Liabilities	$ 2,930,000	$ 990,000	$ 900,000
Accumulated deficit	(3,816,788)	(1,754,191)	(1,555,470)
Total Shareholders' Equity (Deficit)	$ (3,816,662)	$ (1,754,065)	$ (1,555,344)
Ordinary shares subject to possible redemption, shares	4,000,000	4,000,000	4,000,000
Redeemable Common Stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption	$ 40,600,000	$ 40,600,000	$ 40,600,000
Class A common stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	126	126	126
As Previously Reported | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid in capital	5,264,917	5,142,319	5,033,585
Accumulated deficit	(265,097)	(142,500)	(33,779)
Total Shareholders' Equity (Deficit)	$ 5,000,004	$ 5,000,002	$ 5,000,003
Ordinary shares subject to possible redemption, shares	3,418,752	3,431,787	3,442,823
As Previously Reported | Redeemable Common Stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption	$ 34,713,334	$ 34,835,933	$ 34,944,653
As Previously Reported | Class A common stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	184	183	197
Adjustments No.1 | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant Liabilities	2,930,000	990,000	900,000
Additional paid in capital	2,085,130	145,158	55,153
Accumulated deficit	(2,085,162)	(145,162)	$ (55,162)
Total Shareholders' Equity (Deficit)	$ (3)	$ 6
Ordinary shares subject to possible redemption, shares	(288,562)	(97,528)	(88,670)
Adjustments No.1 | Redeemable Common Stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption	$ (2,929,997)	$ (990,006)	$ (900,000)
Adjustments No.1 | Class A common stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	29	10	9
Adjustments No.2 | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid in capital	(7,350,047)	(5,287,477)	(5,088,738)
Accumulated deficit	(1,466,529)	(1,466,529)	(1,466,529)
Total Shareholders' Equity (Deficit)	$ (8,816,663)	$ (6,754,073)	$ (6,555,347)
Ordinary shares subject to possible redemption, shares	869,810	665,741	645,847
Adjustments No.2 | Redeemable Common Stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption	$ 8,816,663	$ 6,754,073	$ 6,555,347
Adjustments No.2 | Class A common stock | Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	$ (87)	$ (67)	$ (80)

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Statement of Operations (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance			$ (55,162)
Change in fair value of warrant liabilities			(2,030,000)
Net Loss			$ (2,323,587)	$ (22,672)
Basic weighted average shares outstanding, ordinary shares subject to possible redemption			1,393,574	857,534
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption			1,393,574	857,534
Basic net loss per ordinary shares subject to possible redemption			$ (1.68)	$ (0.03)
Diluted net loss per ordinary shares subject to possible redemption			$ (1.68)	$ (0.03)
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ (55,162)	$ (55,162)	$ (55,162)
Change in fair value of warrant liabilities	(90,000)	(90,000)	(2,030,000)
Net Loss	$ (254,362)	$ (260,990)	$ (2,323,587)
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,298,261	1,199,781	1,214,918
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,298,261		1,214,918
Basic net loss per ordinary shares subject to possible redemption	$ (0.96)	$ (1.84)	$ (2.05)
Diluted net loss per ordinary shares subject to possible redemption	$ (0.96)	$ (1.84)	$ (2.05)
Restatement of the Company's Financial Statements | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss	$ (109,200)	$ (115,828)	$ (238,425)
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,577,353	1,193,856	1,353,312
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,577,353	1,193,856	1,353,312
Basic net loss per ordinary shares subject to possible redemption	$ (0.07)	$ (0.10)	$ (0.19)
Diluted net loss per ordinary shares subject to possible redemption	$ (0.07)	$ (0.10)	$ (0.19)
Restatement of the Company's Financial Statements | Adjustments No.1
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ (55,162)	$ (55,162)	$ (55,162)
Change in fair value of warrant liabilities	(90,000)	(90,000)	(2,030,000)
Net Loss	$ (145,162)	$ (145,162)	$ (2,085,162)
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	62,648	21,035	40,262
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	62,648	21,035	40,262
Basic net loss per ordinary shares subject to possible redemption	$ (0.09)	$ (0.12)	$ (1.49)
Diluted net loss per ordinary shares subject to possible redemption	$ (0.09)	$ (0.12)	$ (1.49)
Restatement of the Company's Financial Statements | Adjustments No.2
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	(341,740)	(15,110)	(178,656)
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	(341,740)	(15,110)	(178,656)
Basic net loss per ordinary shares subject to possible redemption	$ (0.80)	$ (1.62)	$ (0.37)
Diluted net loss per ordinary shares subject to possible redemption	$ (0.80)	$ (1.62)	$ (0.37)
Restatement of the Company's Financial Statements | Ordinary share subject to redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Basic weighted average shares outstanding, ordinary shares subject to possible redemption			(1,704,918)
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption			1,704,918
Restatement of the Company's Financial Statements | Ordinary share subject to redemption | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Basic weighted average shares outstanding, ordinary shares subject to possible redemption			(3,436,356)
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption			3,436,356
Restatement of the Company's Financial Statements | Ordinary share subject to redemption | Adjustments No.1
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Basic weighted average shares outstanding, ordinary shares subject to possible redemption			93,861
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption			(93,861)
Restatement of the Company's Financial Statements | Ordinary share subject to redemption | Adjustments No.2
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Basic weighted average shares outstanding, ordinary shares subject to possible redemption			1,637,577
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption			(1,637,577)

RESTATEMENT OF PREVIOUSLY ISS_5

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Statement of Cash Flows (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance			$ 55,162
Change in fair value of warrant liabilities			2,030,000
Net Loss			(2,323,587)	$ (22,672)
Initial classification of ordinary shares subject to possible redemption			39,545,230
Change in value of ordinary shares subject to possible redemption			39,545,230
Allocation of offering costs to ordinary shares subject to possible redemption			2,616,574
Accretion of carrying value to redemption value			3,671,344
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	$ 55,162	$ 55,162	55,162
Change in fair value of warrant liabilities	90,000	90,000	2,030,000
Net Loss	(254,362)	(260,990)	(2,323,587)
Change in value of ordinary shares subject to possible redemption		39,545,230	39,545,230
Allocation of offering costs to ordinary shares subject to possible redemption		2,616,574	2,616,574
Accretion of carrying value to redemption value		3,671,344	3,671,344
Restatement of the Company's Financial Statements | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net Loss	(109,200)	(115,828)	(238,425)
Initial classification of ordinary shares subject to possible redemption		34,944,655	34,944,655
Change in value of ordinary shares subject to possible redemption		(108,722)	(231,319)
Restatement of the Company's Financial Statements | Adjustments No.1
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Offering expenses related to warrant issuance	55,162	55,162	55,162
Change in fair value of warrant liabilities	90,000	90,000	2,030,000
Net Loss	$ (145,162)	(145,162)	(2,085,162)
Change in value of ordinary shares subject to possible redemption		(90,006)	(2,029,999)
Restatement of the Company's Financial Statements | Adjustments No.2
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Initial classification of ordinary shares subject to possible redemption		(34,944,655)	(34,944,655)
Change in value of ordinary shares subject to possible redemption		39,743,958	41,806,548
Allocation of offering costs to ordinary shares subject to possible redemption		2,616,574	2,616,574
Accretion of carrying value to redemption value		$ 3,671,344	$ 3,671,344

RESTATEMENT OF PREVIOUSLY ISS_6

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Statement of Changes in Shareholder's Equity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Allocation of offering costs to ordinary share subject to redemption		$ 2,616,574
Accretion of carrying value to redemption value (As restated)		(3,671,344)
IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		37,353,335
Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		2,600,000
Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor			$ (115)
Allocation of offering costs to ordinary share subject to redemption		2,616,574
Accretion of carrying value to redemption value (As restated)		(2,204,815)
Additional paid-in capital | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		37,352,935
Additional paid-in capital | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		2,599,974
Accumulated deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor			$ 0
Allocation of offering costs to ordinary share subject to redemption		0
Accretion of carrying value to redemption value (As restated)		(1,466,529)
Accumulated deficit | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		0
Accumulated deficit | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor		0
Restatement of the Company's Financial Statements
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	$ (39,545,230)	(39,545,230)
Allocation of offering costs to ordinary share subject to redemption	2,616,574	2,616,574
Accretion of carrying value to redemption value (As restated)	(3,671,344)	(3,671,344)
Restatement of the Company's Financial Statements | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	37,353,335	37,353,335
Restatement of the Company's Financial Statements | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	2,600,000	2,600,000
Restatement of the Company's Financial Statements | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(39,544,830)	(39,544,830)
Allocation of offering costs to ordinary share subject to redemption	2,616,574	2,616,574
Accretion of carrying value to redemption value (As restated)	(2,204,815)	(2,204,815)
Restatement of the Company's Financial Statements | Additional paid-in capital | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	37,352,935	37,352,935
Restatement of the Company's Financial Statements | Additional paid-in capital | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	2,599,974	2,599,974
Restatement of the Company's Financial Statements | Accumulated deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accretion of carrying value to redemption value (As restated)	(1,466,529)	(1,466,529)
Restatement of the Company's Financial Statements | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(34,835,933)	(34,713,334)
Restatement of the Company's Financial Statements | As Previously Reported | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	37,353,335	37,353,335
Restatement of the Company's Financial Statements | As Previously Reported | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	2,600,000	2,600,000
Restatement of the Company's Financial Statements | As Previously Reported | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(34,835,590)	(34,712,992)
Restatement of the Company's Financial Statements | As Previously Reported | Additional paid-in capital | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	37,352,935	37,352,935
Restatement of the Company's Financial Statements | As Previously Reported | Additional paid-in capital | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	2,599,974	2,599,974
Restatement of the Company's Financial Statements | Adjustments No.1
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	990,006	2,929,997
Restatement of the Company's Financial Statements | Adjustments No.1 | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	70,000	(774,838)
Restatement of the Company's Financial Statements | Adjustments No.1 | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	(70,000)	(70,000)
Restatement of the Company's Financial Statements | Adjustments No.1 | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	989,996	2,929,968
Restatement of the Company's Financial Statements | Adjustments No.1 | Additional paid-in capital | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	70,000	(774,838)
Restatement of the Company's Financial Statements | Adjustments No.1 | Additional paid-in capital | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	(70,000)	(70,000)
Restatement of the Company's Financial Statements | Adjustments No.2
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(5,699,303)	(7,761,893)
Allocation of offering costs to ordinary share subject to redemption	2,616,574	2,616,574
Accretion of carrying value to redemption value (As restated)	(3,671,344)	(3,671,344)
Restatement of the Company's Financial Statements | Adjustments No.2 | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	(70,000)	774,838
Restatement of the Company's Financial Statements | Adjustments No.2 | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	70,000	(70,000)
Restatement of the Company's Financial Statements | Adjustments No.2 | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares subject to possible redemption (in value)	(5,699,236)	(7,761,806)
Allocation of offering costs to ordinary share subject to redemption	2,616,574	2,616,574
Accretion of carrying value to redemption value (As restated)	(2,204,815)	(2,204,815)
Restatement of the Company's Financial Statements | Adjustments No.2 | Additional paid-in capital | IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	(70,000)	774,838
Restatement of the Company's Financial Statements | Adjustments No.2 | Additional paid-in capital | Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor	70,000	(70,000)
Restatement of the Company's Financial Statements | Adjustments No.2 | Accumulated deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accretion of carrying value to redemption value (As restated)	$ (1,466,529)	$ (1,466,529)

RESTATEMENT OF PREVIOUSLY ISS_7

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Statement of Changes in Shareholder's Equity (Parenthetical) (Details) - shares	Apr. 12, 2021	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)	260,000
IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)		4,000,000	4,000,000	4,000,000	4,000,000
IPO | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)			4,000,000	4,000,000	4,000,000
Private placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)		260,000	260,000	260,000	260,000
Private placement | Additional paid-in capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)			260,000	260,000	260,000

RESTATEMENT OF PREVIOUSLY ISS_8

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Additional Information (Details) - USD ($)	Apr. 12, 2021	Dec. 31, 2020
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
Minimum net tangible assets		$ 5,000,001
Issuance of ordinary shares to Sponsor (in Shares)	260,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)shares
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Initial public offering, offering costs	$ 2,646,665
Underwriting fee	1,000,000
Deferred underwriting fee	1,000,000
Other offering cost	646,665
Unrecognized Tax Benefits	0
Unrecognized tax benefits, interest and penalty accrued	0
Tax provision	0
Federal depository insurance coverage	$ 250,000
Purchase an aggregate of ordinary shares | shares	1,300,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of net loss per share presented in the statement of operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerators:
Net Loss	$ (2,323,587)	$ (22,672)
Accretion of carrying value to redemption value	(3,671,344)
Net loss including accretion of carrying value to redemption value	$ (5,994,931)	$ (22,672)
Denominators:
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,393,574	857,534
Diluted weighted average shares outstanding, ordinary shares subject to possible redemption	1,393,574	857,534
Basic net income (loss) per ordinary share	$ (1.68)	$ (0.03)
Diluted net income (loss) per ordinary share	$ (1.68)	$ (0.03)
Redeemable Common Stock
Numerators:
Accretion of carrying value to redemption value	$ 3,671,344
Allocation of net loss including carrying value to redemption value	(3,500,495)
Allocation of net income (loss)	$ 170,851
Denominators:
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,704,918
Basic net income (loss) per ordinary share	$ 0.10
Non-Redeemable Common Stock
Numerators:
Allocation of net loss including carrying value to redemption value	$ (2,494,438)
Allocation of net income (loss)	$ (2,494,438)
Denominators:
Basic weighted average shares outstanding, ordinary shares subject to possible redemption	1,214,918	857,534
Basic net income (loss) per ordinary share	$ (2.05)	$ (0.03)

INITIAL PUBLIC OFFERING - Addit

INITIAL PUBLIC OFFERING - Additional Information (Details) - $ / shares	Apr. 12, 2021	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)	260,000
IPO
Subsidiary, Sale of Stock [Line Items]
Issuance of ordinary shares to Sponsor (in Shares)		4,000,000	4,000,000	4,000,000	4,000,000
Unit price					$ 10
Number of ordinary shares per unit					1
Number of public warrants per unit					1
Warrants exercise ratio					0.5
Warrants exercise price					$ 11.50

PRIVATE PLACEMENT - Additional

PRIVATE PLACEMENT - Additional Information (Details) - USD ($)	Apr. 12, 2021	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued (in shares)	260,000
Private placement
Subsidiary, Sale of Stock [Line Items]
Number of common stock issued (in shares)		260,000	260,000	260,000	260,000
Aggregate purchase price					$ 2,600,000
Shares issued price per share		$ 10			$ 10
Sale of unit (in value)					$ 2,600,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Apr. 12, 2021	Feb. 21, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019	Jun. 30, 2019
Related Party Transaction [Line Items]
Number of common stock issued (in shares)	260,000
Common stock, shares, issued				1,260,000		1,150,000
Common stock, shares, outstanding				1,260,000		1,150,000
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination			30 days
Due to related parties				$ 394,590		$ 196,495
General and administrative services expense per month				10,000
Related party transaction, Converted notes upon consummation of a Business Combination				$ 1,500,000
Related party transaction, Converted notes Price per share upon consummation of a Business Combination				$ 10
Related party transaction general and administrative services expenses				$ 50,000
Related party transaction, extension Period of time to consummate a Business Combination				21 months
Related Party Transaction, Proceeds From Exercise Of Shares				$ 1,200,000
Public Price Per share, underwriters' over-allotment option is exercised in full				$ 0.033
Related Party Loans | Working Capital Loans Warrant
Related Party Transaction [Line Items]
Public Price Per share, underwriters' over-allotment option is exercised in full on or prior to the date of the applicable deadline				0.30%
Sponsor
Related Party Transaction [Line Items]
Proceeds from issuance of shares			$ 25,000
Anticipated issuance of founder shares to the Sponsor					1,150,000
Number of common stock issued (in shares)		1,149,999			1
Weighted average number of shares, common stock subject to forfeiture			150,000		150,000
Shares owned by sponsor (in percentage)			20.00%
Common stock, shares, issued				1,000,000
Common stock, shares, outstanding				1,000,000
Percentage of Shares agreed not to transfer, assign or sell			50.00%
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)			$ 12.50
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination			20 days
Percentage of transfer of remaining founder shares based on certain exceptions			50.00%
Due to related parties			$ 24,995	$ 0	$ 24,995	0
Unsecured promissory note
Related Party Transaction [Line Items]
Due to related parties						$ 196,495
Borrowings principal amount		$ 300,000
Due to related parties				$ 394,590
Unsecured promissory note | Maximum
Related Party Transaction [Line Items]
Borrowings principal amount							$ 500,000
Unsecured promissory note | Sponsor
Related Party Transaction [Line Items]
Due to related parties			$ 24,995		$ 24,995

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)	Apr. 12, 2021	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
Number of common stock issued (in shares)	260,000
Underwriting Agreement
COMMITMENTS AND CONTINGENCIES
Underwriter purchase option limitation period		45 days
Underwriter commission (in percentage)		2.50%
Proceeds from issuance of shares to underwriters		$ 1,000,000
Over Allotment Option | Underwriting Agreement
COMMITMENTS AND CONTINGENCIES
Number of common stock issued (in shares)		600,000

SHAREHOLDERS' DEFICIT (Details)

SHAREHOLDERS' DEFICIT (Details)	12 Months Ended
	Dec. 31, 2020USD ($)Vote$ / sharesshares	Jul. 28, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Feb. 21, 2019$ / sharesshares
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000,000		1,000,000	1,000,000
Preferred stock, par or stated value per share | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, shares authorized	100,000,000		100,000,000	100,000,000
Common stock, par or stated value per share | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption, shares	4,000,000
Number of votes per share | Vote	1
Common stock, shares, issued	1,260,000		1,150,000
Common stock, shares, outstanding	1,260,000		1,150,000
Common stock value | $	$ 126		$ 115
Ordinary shares
Class of Stock [Line Items]
Ordinary shares subject to possible redemption, shares	4,000,000		0
Common stock, shares, issued	1,260,000		1,150,000
Common stock, shares, outstanding	1,260,000		1,150,000
Unit Purchase Option
Class of Stock [Line Items]
Common stock, shares, issued		240,000
Unit price | $ / shares		$ 11
Underwriter Commission | $		$ 100
Common stock value | $		$ 2,640,000

WARRANTS - Warrants activity (D

WARRANTS - Warrants activity (Details) - 10K/A	12 Months Ended
	Dec. 31, 2020$ / shares
Class of Stock [Line Items]
Warrants redemption price	$ 0.01
Sale price of the ordinary shares	$ 16.50
Minimum
Class of Stock [Line Items]
Written notice of redemption to each Public Warrant holder	20 days
Maximum
Class of Stock [Line Items]
Written notice of redemption to each Public Warrant holder	30 days
Closing of business combination
Class of Stock [Line Items]
Unit price	$ 9.20
Percentage of gross proceeds on additional issuance of shares	60.00%
Period In Which Private Warrants will not Be Transferable	30 days
Market value below $ 9.20 | Closing of business combination
Class of Stock [Line Items]
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	115.00%
Market value $ 16.50 | Closing of business combination
Class of Stock [Line Items]
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	165.00%
Warrants
Class of Stock [Line Items]
Sale price of the ordinary shares	$ 16.50

WARRANTS - Additional Informati

WARRANTS - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020$ / shares
WARRANTS
Warrants redemption price	$ 0.01
Sale price of the ordinary shares	$ 16.50
Maximum
WARRANTS
Written notice of redemption to each Public Warrant holder	30 days
Minimum
WARRANTS
Written notice of redemption to each Public Warrant holder	20 days
Closing of business combination
WARRANTS
Unit price	$ 9.20
Percentage of gross proceeds on additional issuance of shares	60.00%
Period In Which Private Warrants will not Be Transferable	30 days
Closing of business combination | Market value below $ 9.20
WARRANTS
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	115.00%
Closing of business combination | Market value $ 16.50
WARRANTS
Exercise price of the warrants will be adjusted of the higher of the market value (in percentage)	165.00%
Warrants
WARRANTS
Sale price of the ordinary shares	$ 16.50

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	$ 2,930,000
Fair value transfer out of level 3	190,000
Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	2,930,000
Fair Value, Recurring [Member] | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	2,740,000
Fair Value, Recurring [Member] | Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	190,000
Fair Value, Recurring [Member] | Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	2,740,000
Fair Value, Recurring [Member] | Level 1 | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	2,740,000
Fair Value, Recurring [Member] | Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	190,000
Fair Value, Recurring [Member] | Level 3 | Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant Liabilities	190,000
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	40,615,212
Fair Value, Recurring [Member] | US Treasury Securities [Member] | Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	$ 40,615,212

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Mar. 24, 2022	Feb. 02, 2022	Dec. 31, 2020	Dec. 31, 2021	Sep. 24, 2021	Aug. 31, 2021	Jul. 21, 2021
Subsequent Event [Line Items]
Related party transaction, Amount deposited into trust account by sponsor			$ 133,334
Unsecured promissory note				$ 800,004	$ 800,004	$ 800,004	$ 800,004
Subsequent event
Subsequent Event [Line Items]
Related party transaction, Amount deposited into trust account by sponsor	$ 400,002	$ 400,002
Public Price Per share, For Deposit Into Trust Account	$ 0.033	$ 0.033